SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-19-040129
Filing Date
2019-08-14
Accepted
2019-08-14 17:03:49
Documents
71
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tv526882_10q.htm 10-Q 562604
2 EXHIBIT 31.1 tv526882_ex31-1.htm EX-31.1 7890
3 EXHIBIT 32.1 tv526882_ex32-1.htm EX-32.1 4116
  Complete submission text file 0001144204-19-040129.txt   4324476

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT ons-20190630.xml EX-101.INS 672563
5 XBRL TAXONOMY EXTENSION SCHEMA ons-20190630.xsd EX-101.SCH 58576
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ons-20190630_cal.xml EX-101.CAL 36830
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ons-20190630_def.xml EX-101.DEF 261179
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ons-20190630_lab.xml EX-101.LAB 506536
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ons-20190630_pre.xml EX-101.PRE 386100
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 191027439
SIC: 2836 Biological Products, (No Diagnostic Substances)